Therapeutic Antibodies

Monoclonal antibodies
#Biomarkers #Cancer research #Monoclonal antibodies #Oncology #Pancreatic cancer #Phase I trial

‘Encouraging’ data for monoclonal antibody in advanced cancers

Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal… Read More

#Cancer Research #News

Antibodies attack cancer cell
#Antibodies #Cancer research #Cancer Research UK #Collaboration #Oncology #Partnership #UCB

CRUK and UCB advance oncology antibody candidates

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical… Read More

#Cancer Research #News

Neuron and antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antiverse #Drug discovery #Funding #Investment #Machine learning

AI company raises $3m to develop antibodies targeting GPCRs

Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.  The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary… Read More

#News

#Biologics #Cancer research #Cancer treatment #Immunology #Oncology

Biologics and living drugs: entering a new era of cancer treatment

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More

#Cancer Research #Exclusive Content

Lecanemab
#Alzheimer's #Biogen #Eisai #FDA #GlobalData #Monoclonal antibodies #United States

Uncertainty surrounds monoclonal antibody for Alzheimer’s

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease… Read More

#News #Regulatory

PrismA ELISA kit
#Assay development optimisation & technology #Biopharmaceuticals #Cytiva #Monoclonal antibodies

New PrismA ELISA kit for impurity testing

This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals. … Read More

#News

Research scientists in laboratory
#Abbie #Antibodies #Antibody-based therapeutics #Cancer research #Collaboration #Immunome #Oncology #Partnership

Collaboration to identify up to 10 novel target-antibody pairs

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.  Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More

#Business & Investment #Cancer Research #News

#Antibodies #Antibody #Antibody discovery workflow #Antibody-based therapeutics #Bethyl Laboratories #Drug discovery

Why choose Bethyl antibodies for your R&D

This article is sponsored by Bethyl Laboratories. For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. We are vertically-integrated from immunisation through manufacturing and validation. All of our antibodies are… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

Listen to the first DDW Highlights podcast for 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

This week in drug discovery (2-6 January)

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More

#News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Collaboration #License agreement #Partnership #Precision medicine

Collaboration will combine ADC technology and precision therapeutics

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,… Read More

#Business & Investment #News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

Pancreatic cancer
#Antibodies #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #Pancreatic cancer #Preclinical investigations

Triple immunotherapy eliminates pancreatic tumours

A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer.  In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center… Read More

#Cancer Research #Editor's Choice #News

Antibodies attack Covid-19
#AstraZeneca #Covid-19 #Covid-19 treatment #Immunity #Monoclonal antibodies

Accelerated development for Covid-19 monoclonal antibody

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery.  AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from… Read More

#Covid-19 #News #Trending News

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News